EMEA-000804-PIP01-09-M02
Key facts
| Invented name |
Reyataz
|
| Active substance |
atazanavir sulfate
|
| Therapeutic area |
Infectious diseases
|
| Decision number |
P/0098/2014
|
| PIP number |
EMEA-000804-PIP01-09-M02
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of human immunodeficiency virus (HIV-1) infection
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Bristol-Myers Squibb Pharma EEIG
E-mail: medical.information@bms.com |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|
| Compliance procedure number |
EMEA-C-000804-PIP01-09-M02
|
| Compliance opinion date |
13/02/2015
|
| Compliance outcome |
positive
|